Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizum...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pediatrics (Evanston) Ročník 125; číslo 1; s. e35
Hlavní autori:	Carbonell-Estrany, Xavier, Simões, Eric A F, Dagan, Ron, Hall, Caroline B, Harris, Brian, Hultquist, Micki, Connor, Edward M, Losonsky, Genevieve A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.01.2010
Predmet:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents - therapeutic use Child, Preschool Confidence Intervals Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Infant, Premature Kaplan-Meier Estimate Male Palivizumab Primary Prevention - methods Probability Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - mortality Respiratory Syncytial Virus Infections - prevention & control Risk Assessment Survival Rate Treatment Outcome
ISSN:	1098-4275, 1098-4275
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!